No Photo Available

Last Update

2016-08-14T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Andrew Griffiths?

Prof. Andrew Griffiths

Scientific Founder

HiFiBiO Home

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

HiFiBiO Home

Background Information

Employment History

Professor and Director

Université Louis Pasteur

Partner

INCORE

Expert In Droplet Biochemistry

Medical Research Council

Affiliations

Founder
RainDance Technologies Inc

Education

Ph.D.

Web References (56 Total References)


Prof. Andrew ...

hifibio.com [cached]

Prof. Andrew Griffiths

...
Andrew Griffiths
...
Andrew Griffiths
Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg.
After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995).
This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


HiFiBiO

www.hifibio.com [cached]

Prof. Andrew Griffiths

...
Andrew Griffiths is a Professor of Biochemistry at Ecole Superieure de Physique et Chimie Industrielle de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.


Prof. Andrew ...

www.biomillenia.com [cached]

Prof. Andrew Griffiths

Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After gaining a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge. While there, he co-developed phage display for the selection of human antibodies for therapy, first as a Post-Doctoral Research Fellow (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes and high-throughput screening for drug discovery and diagnostic applications. Andrew is a founder of RainDance Technologies.


Scientific founder Andrew ...

www.biomillenia.com [cached]

Scientific founder Andrew Griffiths (right on picture) explained to Mr. Hollande the BIOMILLENIA ultrahigh-throughput microfluidics platform for developing tailor-made enzymes and production strains.


Prof. Andrew ...

www.biomillenia.com [cached]

Prof. Andrew Griffiths

Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg. After gaining a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge. While there, he co-developed phage display for the selection of human antibodies for therapy, first as a Post-Doctoral Research Fellow (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995). This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes and high-throughput screening for drug discovery and diagnostic applications. Andrew is a founder of RainDance Technologies.

Similar Profiles

Other People with this Name

Other people with the name Griffiths

Seb Griffiths
Bluebet PTY LTD

Michael Griffiths
New Life Church

Quentin Griffiths
Tekron International Ltd

Tom Griffiths
Forest Peoples Programme

Daran Griffiths
Zimmer Holdings Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory